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Mycobacterium tuberculosis currently affects 1/3 of the world’s population. Over the 
past 20 years tuberculosis has become more resistant to all front line drugs used against 
it. Because of this, the threat of Multi Drug Resistant (MDR-TB) and Extensive Drug 
Resistant (XDR-TB) strains has grown greater and emerges as a world health issue. 
Modern travel has greatly facilitated the spread of these resistant strains. For this reason, 
more frontline drugs are urgently needed in the fight against TB infection. High 
Throughput Screening can be used to both find and analyze promising drug candidates. 
Using automation, thousands of compounds can be tested against an attenuated strain of 
Tuberculosis and separate the promising compounds from the ineffective ones. We have 
found a select subset of candidates from our custom built ~52,000 compound diversity 
library which show potent inhibitory effects against our mc
2
-7000 attenuated TB strain. 
These compounds have IC50s ranging from 1.98 µM to 11.3 µM and should be 
considered for future development as drugs against TB. Among the active compounds, 
we have found enrichment for hydrazines, as well as representation of several chemi-
classes including quinolones. To determine possible toxicity issues, we have also vetted 
 iv
these compounds against a strain of human lymphoma; all of our promising compounds 
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1. INTRODUCTION: THE NEED FOR HIGH THROUGHPUT SCREENING 
 Mycobacterium tuberculosis (TB) has plagued mankind for centuries. Currently 
TB infects a new person every second, and greatly afflicts those immunocompromised 
patients (World Health Organization). On the continent of Africa, TB claims the lives of 
70% of those who suffer from AIDS. Tuberculosis also greatly affects victims by its 
latent infection attributes, i.e. its ability to stay dormant in the body for many years 
before becoming symptomatic (1).  
The problems facing TB treatments are symptomatic of the larger issues facing 
medicine with the resistance of popular drugs and treatment of disease. According to the 
Centers for Disease Control, TB will be resistant to all current frontline antibiotics by 
2020. During the increasingly encountered MDR-TB, resistance is observed to at least 
isoniazid (INH) and rifampicin (RIF), the two most powerful frontline drugs. This threat 
of resistance has demanded that research and development expeditiously discover and 
bring new drugs to market to replace or supplement our current treatments. According to 
a 2007 Nature Review in Drug Discovery by Payne et.al it takes approximately 13.5 
years for a drug to make it fully through the Food and Drug Administration approval 
process (2), making the issue of drug development especially urgent. The potential 
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Adding to the urgency of drug development is the fact that the current compounds in the 
development pipeline are derivatives of chemical classes for which there are known 
resistance mechanisms. Developing new, chemically unrelated compounds requires the 
ability to rapidly evaluate compounds across a range of chemical space. High throughput 
screening (HTS) is a powerful tool for quickly assessing the effectiveness of many 
compounds at once (2). It is widely used in industry and is gaining acceptance in 
academia due to its multiple applications, rapidness, and minimization of human error in 
experiments, reproducibility, and quality of data. Most labs which feature a HTS 
program use automation for their screening purposes. While the cost of entry to a 
robotics based HTS program may be high, a lab that makes the required investment can 
progress much faster in the drug discovery process. HTS requires more equipment (like 
robotics) than enzyme based assays, but carries with it several advantages. With an 
enzyme or target based approach, promising inhibitors may bind and show efficacy, but 
in actuality may not be permeable to the cell membrane. This does not translate well into 
a promising drug. With activity based or a HTS approach, by definition the compounds 
which are found to inhibit are both active and cell wall permeable. This can prove to be 
greatly advantageous, as some believe it is an easier process to identify a target for an 
already effective inhibitor versus modifying a compound candidate to confer 
permeability. It is not enough however, to simply gather thousands of compounds 
together and screen them against a specific strain. The real strength of the HTS program 
is in the formation of a diverse library and the generation of high quality, reproducible 
data. Previous whole cell screens have met with varying degrees of success. For 
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instance, the widely known 2009 screen run by Southern Research Institute (SRI) 
featured a library of 100,997 compounds from ChemBridge Corporation (3) . Their 
activity based assay discovered hundreds of promising compounds by sequentially 
screening in lessening concentrations until even the most promising compounds were 
ineffective, in order to generate IC90 values. Out of their 100,000+ compound library, 
they discovered a highly active subgroup of 293 compounds with high IC90 values (<0.1-
1.6 µg/mL). They also discovered multiple representations of different chemi-classes in 
their inhibitor subset, including aminothiazoles, hydroxyquinolones to name a few. In 
many ways our HTS builds upon the screening foundation laid out by the SRI screen. 
Our screen, like theirs, began with the formation of a diversity selected library of drug 
like compounds. We also used Lipinski’s rules as a guide in our selection criteria. In 
contrast, the previously mentioned GlaxoSmithKline (GSK) HTS program of the mid to 
late 1990s spent approximately 1 million USD per screen with 70 target based screens 
performed, yielding only 5 tractable hits which were later discarded from active study 
(4). Their library featured an over representation of certain scaffolds such as nucleoside 
analogs. Their approach in searching only for compounds against specific targets caused 
them to possibly overlook otherwise active compounds with unknown modes of action.  
 Unlike most of the other labs performing screens against MTB, the Sacchettini 
HTS program uses a vaccine strain of TB, mc
2
-7000 instead of wild type H37Rv. This 
doubly attenuated pantothenic knock out strain (     panCD) removes genes required for 
pantothenate synthesis (5) . Pantothenic acid is used in the synthesis of coenzyme A 
(CoA). Coenzyme A acts as an acyl group carrier to form acetyl-CoA and other related 
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compounds; this is a way to transport carbon atoms within the cell. Mc
2
-7000 also 
allows us to perform all of our experiments at a BL2 level due to the region of difference 
one (RD1) deletion which encodes several of the strain’s virulence factors (6). RD1 
locus is absent in all BCG vaccine strains of TB, yet is present in all M. tuberculosis 
strains. The panCD deletion was added as a backup safety step due to the significant 
increase in virulence of vaccine strains which only had the RD1 deletion. It is an 
acknowledged concession that compounds which act upon the virulence pathway(s) will 
probably be overlooked and undetected in our screen because of our model strain. While 
this is less than favorable, the ability to test for all the compounds which are not linked 
to TB’s virulence pathways is still a valuable opportunity. It is also a superior model 
than screening compounds against M. Smegmatis. Understandably this might bring up 
questions as to the results acquired using this strain. It has been shown that the 
differences between mc
2
-7000 and wild type (WT) H37Rv are less than between WT 
and the much used BCG vaccine strain in mouse organ CFU studies (5). We find that, 
properly supplemented with pantothenic acid to account for the panCD deletion, our 
model strain allows us to adequately test whole cell compounds in a high throughput 
method and determine whether each candidate has any inhibitory effects against TB. 
Testing our promising hit subset independently against WT H37Rv would be useful to 
assess the real world benefits of our candidates. Information from whole cell assays 
combined with target identification and crystal structure inhibitor complexes will help in 
the structure activity (SAR) relationship of our validated hit compounds in a rational 
drug design strategy.  
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2. EXPERIMENTAL METHODS AND MATERIALS 
            Our HTS uses the mc
2
-7000 strain of TB (5), courtesy of the Bill Jacobs lab. The 
glycerol stocks of the strain are kept at -80 ° C and a new starter culture is set up every 
week, which is kept at 37 ° C on a shaker in an incubator. Mc
2
-7000 is not virulent, can 
be grown in a BL2 facility, and requires pantothenic acid to grow. The diversity library 
was custom built by the Sacchettini lab in order to acquire promising drug candidates. 
The diversity library consists of compounds from multiple vendors (Chembridge, Chem-
Div, and Enamine) (Fig.2). The compounds were chosen specifically for their 
conformance with a preset criteria based on Lipinski’s rules  for selecting drug like 
compounds (7) as well as their acceptance based on our Tanimoto scoring cutoff (8). It is 
important to note here that Lipinski’s rules were never meant for natural products or 
their analogues, which many of the current TB drugs on the market are derived from. In 
our case the Sac-1 diversity library features no natural products. Tanimoto scoring is a 
similarity calculation which can be run to avoid duplicate representation of compound 
family scaffolds being selected for a library; it can be used to enhance library diversity. 
Tanimoto scoring (also known as Jaccard Similarity and distance index) allows selection 
from a scale of -.5 (all compounds) to 1 (fewest compounds). Our Tanimoto selection 
criterion was 0.7. The compounds were shipped to us as individual powders in a 96 well 
plate format; we converted 4 of these 96 well “mother plates” into one 384 well daughter 
plates (162 of them total), solubilized with 100% DMSO. These plates were then tested 
against the mc
2
-7000 strain (Fig. 4). 
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2.1 Preparation of Starter Culture 
Briefly, a 10 mL starter culture with mc
2
-7000 was grown for ~4 days. The starter 
culture consists of 10mL Difco 7H9 (pH ~7.4), 100 µL dextrose, 1 mL OADC 
(Middlebrook, 212351), 85 µL NaCl (10% solution) 25 µL tween, and 10 µL each of 
malachite green and 1 mM pantothenic acid (50 mg/mL) mixed in a 20 mL capacity ink 
bottle. As a precaution, every starter culture had a sample taken from it and swabbed 
onto a Luria Broth (LB) plate with no antibiotic. This LB plate is placed into an 
incubator at 37 degrees centigrade and is allowed to sit overnight. TB grows much 
slower than other bacteria, so if any growth is observed on the LB contamination check 
plate after only a day, the starter is contaminated and disposed of by filling the culture 
bottle with Environ™ Vesphene™, a tubercidal agent. 
2.2 Preparation of Assay Plates 
Pending verification of non-contamination, 300 µL of this grown starter culture (OD 
~0.6) is added to a 20 mL plate assay solution with the exact same concentrations of 
supplements, sans OADC. Our assay requires 20 mL of 7H9 media per plate, be it 96 
well (200 µL/well) or the more commonly used 384 well (50 µL/well). Therefore, when 
setting up an assay, it might be 500 mL of media being made for the run (20 plates 
worth). 
The screening program features a group of robots that create the 320 compound 
daughter plates, the assay test plates, as well as stain, analyze, and re-plate promising 
compounds for further testing. Chief among these robots is the Cy-Bio Vario, featuring 
96 and 384 well interchangeable heads and a dual rack system for storing and moving 
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plates as they are needed during the assay. The Vario system is enclosed in a HEPA™ 
filtered hood, enabling its use in testing many different strains. One µL of each 
compound was added to a plate well with 49 µL of cell assay solution. Minimum 
(Rifampicin) and maximum (no drug) growth control wells were placed in each plate 
(Fig. 3).  The assay plates were then sealed and stored on a platform shaker in an upright 
incubator (Forma Scientific Incubator model 3282) set for 37 ° C. The plates were grown 
for 6 days, and on the 6th day were stained with 1.25 µL/well of  Cell Titer-Blue™ and 
allowed to incubate for an additional 24 hours. Cell Titer-Blue™ (or Resazurin) is an 
oxidation reduction indicator used in whole cell viability assays (9). It is reduced from 
its normal blue appearance to a pinkish red when test cells are actively respiring in a 
well. 
2.3 Acquiring and Analyzing Assay Data 
On the 7
th
 day, the plates were read using a POLARstar Omega spectrophotometer 
running an absorbance program set to calculate a differential reading at 573nm and 
605nm. The resulting output number, if greater than zero, was designated as an 
ineffective compound against TB, showing growth, (pink). If the resulting number was 
less than zero, the compound was inhibitory towards TB (blue). Data was taken from the 
Omega spectrophotometer as a Comma Delimited (CSV) file and used for sorting and 
calculating plate specific percent controls, as well as mean (Fig. 5.) The data was then 
formatted and uploaded onto the Collaborative Drug Design (CDD) website, where 
further calculations could be performed, including IC50, and heat mapping. The CDD 
website offers our lab a secure cloud environment for storage and analysis of our data, 
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while also giving us the ability to share data and results with colleagues not only in our 
lab but in other collaborating labs as well. It is a powerful tool for our screening program 
(2).                                                   
                                                        2.4 Statistical Analysis 
After recovering the data readouts from the spectrophotometer, it was analyzed and its 
quality determined. Due to the highly variable nature of the whole cell assay, several 
different methods of analyzing the data were taken into consideration. The first way 
which the data was analyzed was to perform a calculation on each plate using the 
percent of control method for each assay well. In essence, we compared the inhibitory 
properties of each drug to the known inhibitory properties of our max control (no drug 
present) and our minimum control (rifampicin present). The following equation was then 
used to calculate the percent inhibition: 
                                          
 
 
                                 (Sample - minimum)                         (Eq. 1) 
                      1    -    __________________________     X    100 =  % inhibition     
(Maximum-minimum) 
 
This method for analyzing the data would have been satisfactory for all of the data run if 
it were not for the fact that the control wells behaved differently not only from run to run 
but occasionally from plate to plate. This caused statistical issues with both the 
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reproducibility and the similarity of the data (Note: we were able to use Equation 1 on 
our potent hit data, described below). We then used an alternative method for analyzing 
the primary screen data, namely the population- mean method. The population-mean 
method takes the individual sample and divides it by the mean of all the samples on the 
plate, with the controls removed.  
The formula: 
                                        
 
                                       (Sample)                              (Eq. 2) 
       1     -        __________________________     X 100                                           
(Mean of samples) 
 
 
As part of the statistical analysis, the plate data was checked for variability between 
different concentrations. The purpose of this was to ensure that the data generated from 
the screens could be compared with itself for consistency and would support legitimate 
conclusions about the data results. To accomplish this, the software Pipeline Pilot was 
used to compare different concentration runs such as 10 µM and 5 µM (Figure 8). The 
more steep the output graph’s slope (0.90 in Figure 8) the higher the consistency of the 
data. If comparisons were made between two sets of identical compounds at the same 
concentration, the ideal slope would be 1, showing complete agreement and 
reproducibility between the two runs. Since the previously stated comparison was made 
between identical compounds at two different concentrations, the .90 slope is acceptable, 
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since it is expected that a certain small amount of compounds would drop out after 
lowering the concentration. In order to ensure the highest quality of data, plates with the 
most potent hits from the Sac-1 library were run three times (3 runs) each in triplicate. 
They were run on different days, with independently made supplements as well as 
different source starter cultures. This data was used to generate the IC50 curves seen in 
Figure 1. The percent control data was plotted in Excel for the curves (using Equation 1) 
and the concentration data was inputted into Pipeline Pilot to generate the IC50 value. 
The minimum control used was Rifampicin and the max control was the wells with no 
compound present. Error bars were calculated by using the Standard Deviation of 
Population (Stdev.P) function in Excel 2010 for each plate.  
2.5 Assay Optimization 
 
The original 20 µM screen was performed with an incubation time totaling 5 days. On 
the 5
th
 day they were stained, with absorbance readings taken on the 6
th
 day. As the data 
was examined it was discovered that the dynamic range on each plate was statistically 
too small (Fig. 5 Cont.). The inhibitor cutoff or minimum was observed to be slightly 
less than zero while the max was only around OD 0.2. In response to this, in the 
secondary screening portion of the HTS program the time of incubation was lengthened 
to allow for more development and growth of the mc
2
-7000 culture in each well. Once 
stained and analyzed, it was observed that the range had nearly doubled to OD ~0.4 (Fig. 
6). This proved to be a much more desirous dynamic range for the statistical analysis and 
became part of the standard operating procedure. The secondary screening also included 
an added supplement of malachite green to combat any contamination that may arise. 
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Malachite green targets E.coli and other harmful bacteria in whole cell cultures and 
proved to be quite valuable in limiting losses and wastes of materials due to 
contamination down time (10).   
            During the secondary phase of screening a robot mixing step was added 
(validated by bromophenol blue). This step occurs immediately after the compounds are 
dispensed into the cell media solution. It is a four step mix for each well with the plate 
shifting as 20 uL are aspirated and dispensed in each corner of the well. It ensures a full 































The preliminary 20 µM screen yielded many hits which showed activity against 
mc
2
-7000 (Fig. 7). These hits were re-plated using an EP-Motion robot which cherry 
picked the promising leads from the daughter plates into a fresh plate containing only 
hits. Compounds were then tested again at lower concentrations and at each decreasing 
level of concentration the hits that did not inhibit mc
2
-7000 growth were removed from 
further testing. At 10 µM we detected ~700 compounds which had activity against TB. 
At 5 µM we detected ~350 active compounds. At 1.25 µM we detected 174 compounds, 
and at 0.625 µM we detected 107 compounds. These compounds were then re-plated and 
tested in another dilution screen beginning with 10 µM and continuing serially 
downward to 9 nM. At the two lowest concentrations, no hits showed activity. To ensure 
good quality data, the most potent hits (21 compounds) were tested in 3 runs (triplicate 
for each run). IC50s were calculated using Pipeline Pilot (11) and graphs were generated 
in Excel 2010 (Fig. 1). Another subset of less potent compounds is presented in Figure 
10. Percent of Control values were determined using Equation 1. These promising 
compounds also were run against two cytotoxicity screens; the WT 2561 strain of the 
human lymphoma cell line (12) (at a concentration of 5 µM) and a human fibroblasts 
screen. All of the top compounds were beneath the lethal threshold established in both 
toxicity screens. The top ranked compound, CD:0325-0400 (2,2'-(E)-diazene-1,2-
diyldiphenol) (Figure 9) has been used in previous research (13) to validate what is 
called a “molecular keypad lock.” It functions as a mono-phosphate chemo-sensor. 
Many other compounds which had inhibitory properties against TB have other known 
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properties or patents, such as the second best compound by IC50  CB:5538347 (1-methyl-
2-[3-(1-methyl-1H-benzimidazol-2-yl)triaz-1-en-1-yl]-1H-benzimidazole) has patents 
pending or approved. Many of our compounds might have broad based implications 
against other diseases. Using a clustering algorithm, we determined the overall 
abundance of certain chemi-classes in our library. We observed that one of our top hits, 
EN-T5387803 was a quinolone (Fig. 10). This is surprising considering the extremely 
low abundance in the general library population. Only 227 quinolones are present in the 
entire 51K Sac-1 library (~0.45%).  Quinolones (and fluoroquinolones) are 
chemotherapeutic drugs, which kill bacteria by interfering with DNA replication, mainly 
by inhibition of DNA gyrase. DNA gyrase belongs to a class of enzymes known as 
topoisomerases enzymes (14) . These enzymes are highly essential for the catalyzation 
required for DNA replication, transcription, and recombination in prokaryotic and 
eukaryotic cells. This differs from other drugs such as penicillin and cephalosporin 
which inhibit cell wall biosynthesis. Ciprofloxacin is an example of an antibiotic in the 
fluoroquinolone class (15). Quinolones are still being investigated for their inhibitory 
abilities; novel synthetic quinolones have recently been reported which inhibit M. 
tuberculosis and rapid-growing mycobacteria as well as methicillin-resistant S. aureus, 
while showing no inhibition for E. coli and P. aeruginosa, suggesting a specific uracil 
binding site (16). Of the top compounds, we observed an enrichment of hydrazines. 
Considering only 5,528 compounds out of the total 51K library fit this class (~10%), it is 
notable that over 50% of our top hits were hydrazines. Isoniazid (INH), a front line anti-
tuberculosis drug is a hydrazine, so further testing (perhaps against an INH resistant 
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strain) should be performed on these hydrazines to observe whether they possess the 
same mode of action. Some current frontline drugs such as INH require bioactivation to 
be effective. These types of drugs are known as prodrugs. For example, INH must be 
activated by a bacterial catalase-peroxidase enzyme called KatG. KatG couples the 
isonicotinic acyl with nicotinamide adenine dinucleotide (NADH) to form isonicotinic 
acyl-NADH complex. This complex tightly binds to the enoyl-acyl carrier protein 
reductase InhA, which blocks the natural enoyl-AcpM substrate and the action of fatty 
acid synthase. This process inhibits the synthesis of mycolic acid, required for the 
mycobacterial cell wall (17) . INH is most often given in a regimen combination with 
other frontline or second line drugs dependent on type of TB. Drug regimens which use 
only single drugs result in rapid resistance development and treatment failure. 
           Out of our top compounds, four (CB:5109296, EN:T5996673, CD:8010-0479 and 
EN:T6076227) have the scaffolding required to be prodrugs. These 4 compounds have 
the necessary hydrolyzing groups to degrade and demonstrate their efficacy in vitro. 
Recent research illustrates that esters (lipophilic specifically) have shown more activity 
(in concentrations 10 fold lower) against TB than current drugs including pyrazinamide, 
while still easily activated by mycobacterial enzymes (18). There is still much discussion 
in the drug development community as to whether prodrugs are desirable candidates. 
Many frontline drugs are prodrugs, such as INH.  The major argument put forth against 
prodrugs is that it is easier to develop resistance to them versus other conventional 
classes. It has been previously reported that INH encounters resistance on the order of 
1/1,000,000 organisms, while Rifampicin encounters resistance in 1/100,000,000 (19). 
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Also, the overwhelming majority of mutations that confer resistance to drugs requiring 
activation affect the activation process, not the target (19). This would infer that 
prodrugs would be more affected than other drug classes with resistance problems. 
          Overall many of the known chemi-classes of current use tuberculosis drugs are 
represented in our candidate subset. While seeing similarities between candidate and 
frontline drug may give us a hint as to target and mode of action, the presence of 
previously unseen chemi-classes and emerging compound families gives us insight into 






























4. DISCUSSION AND CONCLUSIONS 
 
          The screening program yielded several promising candidates that can continue to 
mouse studies or direct application studies against Mtb H37Rv. Target identification 
using mutagenesis or further screening studies is a natural progression for these 
compounds based on the data acquired from this screening program. Previous screening 
approaches have been a process in which the goal was to choose a target and then find 
compounds which were active against it. Our HTS program chose in essence a strategy 
that was the reverse of that. The goal of the Sacchettini HTS program was to first and 
foremost find promising compound candidates which not only were effective against 
TB, but also were specifically targeting a portion of the TB genome. The hope is that 
when the active compounds are matched with their identified targets, we will be able to 
structurally optimize and design new pharmaceuticals which will be less prone to 
resistance (or lengthens the time before resistance develops), less toxic, and efficient at 
lower clinical doses. Another opportunity for our promising compounds is to pair them 
with known TB treatments to determine whether they work in synergy. The future of 
effective TB treatment may very well be the reapplication of a compound that is 
ineffective due to resistance, coupled with a new compound that allows efficacy to 
return. Our secondary screen with human lymphoma cells and fibroblasts allowed us to 
remove compounds which were killing the bacteria due to toxicity. The remaining 
compounds are promising compounds (due to their non-toxicity, combined with their 
reproducible effectiveness against our TB strain) and are desirable candidates for further 
study. 
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It is a fact that Tuberculosis greatly affects the poorer regions of our planet. The 
people who suffer worst from TB are those who have very little money, little to no 
access to pure drinking water, and live in areas with poor public health programs (20). 
For these reasons, many drug companies have pulled out of anti-TB drug development. 
Simply put, it is more rewarding financially for drug companies to target diseases and 
conditions whose sufferers (and their insurance) can afford much greater prices for their 
care, versus poor people who cannot afford medicine. This unfortunate truth demands 
that the scientific community come up with novel solutions and more efficient ways to 
develop treatments for these “poor” diseases. High Throughput Screening allows an 
academic lab to function and analyze large batches of compounds for leads much like a 
pharmaceutical company, but is freer of the financial considerations of a large company. 
By using HTS it is conceivable that the academic research of today could lead to a base 




1. de Steenwinkel, J. E. M., de Knegt, G. J., ten Kate, M. T., van Belkum, A., 
Verbrugh, H. A., Kremer, K., van Soolingen, D., and Bakker-Woudenberg, I. A. 
J. M. (2010) Journal of Antimicrobial Chemotherapy 65, 2582-2589 
 
2. Ekins, S., Bradford, J., Dole, K., Spektor, A., Gregory, K., Blondeau, D., 
Hohman, M., and Bunin, B. A. (2010) Molecular BioSystems 6, 840-851 
 
3. Ananthan, S., Faaleolea, E. R., Goldman, R. C., Hobrath, J. V., Kwong, C. D., 
Laughon, B. E., Maddry, J. A., Mehta, A., Rasmussen, L., Reynolds, R. C., 
Secrist Iii, J. A., Shindo, N., Showe, D. N., Sosa, M. I., Suling, W. J., and White, 
E. L. (2009) Tuberculosis 89, 334-353 
 
4. Payne, D. J., Gwynn, M. N., Holmes, D. J., and Pompliano, D. L. (2007) Nat Rev 
Drug Discov 6, 29-40 
 
5. Sambandamurthy, V. K., Derrick, S. C., Hsu, T., Chen, B., Larsen, M. H., 
Jalapathy, K. V., Chen, M., Kim, J., Porcelli, S. A., Chan, J., Morris, S. L., and 
Jacobs, J. W. R. (2006) Vaccine 24, 6309-6320 
 
6. Junqueira-Kipnis, A. P., Basaraba, R. J., Gruppo, V., Palanisamy, G., Turner, O. 
C., Hsu, T., Jacobs, W. R., Fulton, S. A., Reba, S. M., Boom, W. H., and Orme, 
I. M. (2006) Immunology 119, 224-231 
 
7. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (2001) 
Advanced Drug Delivery Reviews 46, 3-26 
 
8. Searls, D. B. (2010) PLoS Comput Biol 6, e1000809 
 
9. Czekanska, E. M. (2011) Assessment of Cell Proliferation with Resazurin-Based 
Fluorescent Dye. in Mammalian Cell Viability (Stoddart, M. J. ed.), pp 27-32, 
Humana Press, New York 
 
10. Brovko, L., Meyer, A., Tiwana, A. S., Chen, W., Liu, H., Filipe, C. D. M., 
Griffiths, M.W., (2009) Journal of Food Protection 72, 1020-1024 
 
11. Altintas, I., Berkley, C., Jaeger, E., Jones, M., Ludascher, B., and Mock, S. 
(2004) Kepler: an extensible system for design and execution of scientific 
workflows. in Proceedings of 16th International Conference on Scientific and 
Statistical Database Management, 2004.  
 
12. Maxwell, S. A., Li, Z., Jaya, D., Ballard, S., Ferrell, J., and Fu, H. (2009) Journal 
of Biological Chemistry 284, 22379-22389 
 19
 
13. Wang, J., and Ha, C.-S. (2010) Analyst 135, 1214-1218 
 
14. Appelbaum, P. C., and Hunter, P. A. (2000) International Journal of 
Antimicrobial Agents 16, 5-15 
 
15. Bolon, M. K. (2011) The Medical Clinics of North America 95, 793-817 
 
16. Guzman, J. D., Wube, A., Evangelopoulos, D., Gupta, A., Hüfner, A., 
Basavannacharya, C., Rahman, M. M., Thomaschitz, C., Bauer, R., McHugh, T. 
D., Nobeli, I., Prieto, J. M., Gibbons, S., Bucar, F., and Bhakta, S. (2011) Journal 
of Antimicrobial Chemotherapy,66,1766-1772 
 
17. Miesel, L., Rozwarski, D. A., Sacchettini, J. C., and Jacobs Jr, W. R. (1998) 
Novartis Found Symp 217, 209-220; discussion 220-201 
 
18. Simões, M. F., Valente, E., Gómez, M. J. R., Anes, E., and Constantino, L. 
(2009) European Journal of Pharmaceutical Sciences 37, 257-263 
 
19. Barry, C. E., Slayden, R. A., Sampson, A. E., and Lee, R. E. (2000) Biochemical 
Pharmacology 59, 221-231 
 






































IC50: 1.979 μM 
Figure 1 Top Hits by IC50 
 22
CD:8010-0479      
IC50: 2.244 μM  
EN:T0504-2786   








































   
Figure 1. continued. 
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CB:5538347  


































: 3.777 μM 
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EN:T0517-5930 
IC50: 5.209 μM 
EN:T5996673  
IC50: 4.735 μM 
 
Figure 1. continued. 
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CB:5727013  
: 5.583 μM IC50 
CB:5549443  




Figure 1. continued. 
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EN:T0512-9721 
IC50: 6.898 μM 
EN:T5387803  
IC50: 6.122 μM 
 
Figure 1. continued. 
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IC50: 8.919 μM  
Figure 1. continued. 
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EN:T5864236 
IC50: 8.977 μM 
EN:T6076227             
IC50 : 9.111 μM 
Figure 1. continued. 
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CD:4896-3353 
 IC50: 10.31 μM 
EN:T0517-5638 
 IC50: 10.06 μM 
Figure 1. continued. 
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CB:5630707 
IC50: 11.06 μM 





IC50: 11.31 μM 



















































Figure 3. General layout of 384 well HTS Plate. 
 
 
The pink columns (1 and 24) hold the “max” controls, which are wells that contain no 
drugs. After optimization we were pleased to find that the OD was ~ 0.4. The red 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Sample scatter plot from 20 µM run 
 
 











































































                    
  























































Figure 9. Library Characteristics. 
 







Figure 9. continued. 
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